118 related articles for article (PubMed ID: 29672160)
21. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
Ma Y; Wink M
Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284
[TBL] [Abstract][Full Text] [Related]
22. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
Stark M; Assaraf YG
Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003
[TBL] [Abstract][Full Text] [Related]
23. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
[TBL] [Abstract][Full Text] [Related]
24. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
[TBL] [Abstract][Full Text] [Related]
26. Butylcycloheptylprodigiosin and undecylprodigiosin are potential photosensitizer candidates for photodynamic cancer therapy.
Arshadi Z; Hosseini SA; Fatehi D; Mirzaei SA; Elahian F
Mol Biol Rep; 2021 Aug; 48(8):5965-5975. PubMed ID: 34331180
[TBL] [Abstract][Full Text] [Related]
27. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
Sakata S; Fujiwara M; Ohtsuka K; Kamma H; Nagane M; Sakamoto A; Fujioka Y
Oncol Rep; 2011 Feb; 25(2):333-9. PubMed ID: 21165575
[TBL] [Abstract][Full Text] [Related]
28. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
29. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
32. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
[TBL] [Abstract][Full Text] [Related]
33. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
34. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
35. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
37. Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin.
Darzi S; Mirzaei SA; Elahian F; Peymani A; Rahmani B; Pishkhan Dibazar S; Shirian S; Shakeri Chaleshtori L; Aali E
Mol Biol Rep; 2021 Nov; 48(11):7105-7111. PubMed ID: 34564803
[TBL] [Abstract][Full Text] [Related]
38. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
39. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
40. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
